Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02624258 · ClinicalTrials.gov registry record · Early Phase 1
Pilot Study of Non-Viral, RNA-Redirected Autologous T Cells in Patients With Refractory or Relapsed Hodgkin Lymphoma
A Early Phase 1 study, sponsored by University of Pennsylvania.
- Terminated
- Registry status
- Early Phase 1
- Development phase
- 2
- Enrollment target
NCT02624258: Clinical Trial Early Phase 1 study, sponsored by University of Pennsylvania.
NCT02624258 is a Early Phase 1 study that was terminated before completion, run by University of Pennsylvania. The registered enrollment target is 2 participants, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (96% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02624258, a Early Phase 1 study, was terminated before completion, sponsored by University of Pennsylvania.
- TERMINATED
- Registry status
- Early Phase 1
- Development phase
- 2 participants
- Enrollment target
Study Summary
Pilot open-label study to estimate the feasibility, safety and efficacy of intravenously administered, RNA electroporated autologous T cells expressing CD19 chimeric antigen receptors expressing tandem TCRζ and 4-1BB (TCRζ /4-1BB) costimulatory domains (referred to as "RNA CART19") in Hodgkin Lymphoma (HL) patients. Subjects will be treated with IV administration of RNA anti-CD19 CAR T cells for a total of six doses over 3 weeks.
Primary Outcome
Occurrence of study related adverse events, defined as NCI CTCAE V4 \> grade 3 signs/symptoms, laboratory toxicities and clinical events that are possible, likely or definitely related to study treatment at any time from the first cyclophosphamide infusion until Month 4.
Interventions
- BIOLOGICAL CD19 RNA redirected autologous T-cells (RNA CART19 cells)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2015-11 |
| Est. Completion | 2019-12-06 |
| Phase | Early Phase 1 |
Why NCT02624258 stopped before completion
NCT02624258 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 2 participants, a relatively small participant target, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (96% lower).
The record links to 0 conditions, and to 1 intervention - of which CD19 RNA redirected autologous T-cells (RNA CART19 cells) is the first listed.
NCT02624258 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02624258 about?
NCT02624258 is a clinical study titled "Pilot Study of Non-Viral, RNA-Redirected Autologous T Cells in Patients With Refractory or Relapsed Hodgkin Lymphoma". Pilot open-label study to estimate the feasibility, safety and efficacy of intravenously administered, RNA electroporated autologous T cells expressing CD19 chimeric antigen receptors expressing tandem TCRζ and 4-1BB (TCRζ /4-1BB) costimulatory domains (referred to as "RNA CART19") in Hodgkin Lympho...
What is the current status of trial NCT02624258?
This trial is currently terminated. It is a Early Phase 1 study. The enrollment target is 2 participants. The study started on 2015-11. Estimated completion is 2019-12-06.
What interventions are being tested in trial NCT02624258?
The interventions under investigation include: CD19 RNA redirected autologous T-cells (RNA CART19 cells) (BIOLOGICAL).
Who is sponsoring clinical trial NCT02624258?
This trial is sponsored by University of Pennsylvania, which has 1,423 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02624258's enrollment target sits among peer trials
2 1973rd of 2000 higher than 16 of 2,000 other Early Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Early Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia